Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2006 | Varian

Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2006

PALO ALTO, Calif., April 25 /es/es/es/es/es/es/es/PRNewswire-FirstCall/es/es/es/es/es/es/es/ -- Varian Medical Systems (NYSE: VAR) today is reporting another solid quarter with growth in net orders, revenues, net earnings, and backlog for the second quarter of fiscal year 2006. Including the impact of stock option expensing, the company generated net earnings of $56 million or $0.41 per diluted share for the quarter. Excluding option expensing of approximately $7 million or $0.05 per diluted share, net earnings were $63 million or $0.46 per diluted share. Earnings for the second quarter of fiscal 2005 were $54 million or $0.39 per diluted share.

"Excluding the impact of option expensing initiated this fiscal year, second quarter net earnings per diluted share grew by 18 percent over the year-ago quarter," said Tim Guertin, President and CEO of Varian Medical Systems. "The second quarter was marked by strong revenue growth in our Oncology Systems and X-Ray Products businesses with solid contributions from some of our emerging businesses in brachytherapy and flat-panel digital image detectors for filmless X-rays."

Second-quarter revenues for the company were an all-time record $414 million, up 18 percent from revenues of $351 million in the same period in fiscal 2005. Net orders for the quarter were $429 million, up 9 percent from the year-ago quarter. Backlog at the end of the quarter stood at a record $1.3 billion, 20 percent higher than at the end of the second quarter of fiscal 2005.

The company generated strong cash flow from operations in the second quarter and ended the quarter with $394 million in cash and marketable securities. The company spent $85 million during the period to repurchase 1.5 million shares of its common stock. Days sales outstanding at the end of the quarter was 82, up 2 days from the same time last fiscal year, but down 10 days from the end of the first quarter of this fiscal year.

Oncology Systems

Oncology Systems' second quarter revenues totaled $346 million, up 18 percent from the second quarter of last fiscal year. This business recorded second-quarter net orders of $365 million, up 8 percent from the same period last year. Net orders were up 20 percent in North America and down 4 percent in international regions for the quarter.

"Net orders were up strongly in North America with continuing demand for our products for image-guided radiation therapy and stereotactic radiosurgery," said Guertin, adding that as of the end of the second quarter the company had more than quadrupled worldwide installations of its On-Board Imager product for IGRT over the past year with more than 200 complete or in progress. "Outside North America, orders were up except in Asia where we had exceptionally strong growth in the year-ago quarter. For the first half of this fiscal year, net orders for Oncology Systems are up 13 percent, including 18 percent in North America and 7 percent in international regions, which is in line with our long-term global growth expectations for this business."

Due to significant growth in our new product shipments and a continued shift toward international deliveries in Oncology Systems, the business experienced an increase in revenues that were deferred until installations are complete. This reduced gross margin by approximately one percentage point during the second quarter. "Over the longer term I expect our gross margins will benefit as these products mature and installation cycles shorten," Guertin said.

X-Ray Products

Revenues for the X-Ray Products business, including X-ray tubes and flat panel digital image detectors for filmless X-rays, were a record $61 million for the second quarter, up 21 percent from the year-ago quarter. "Our emerging business in digital image detectors nearly doubled during the quarter, driven by demand in medical diagnostics, dental CT scanning, and veterinarian care," Guertin said. Meanwhile revenues from X-ray tubes, particularly high-power anode-grounded CT tubes, also grew. "Gross margin for this business grew by two percentage points with the help of dynamic growth in our digital detector shipments," Guertin said.

Other Businesses

The company's Security and Inspection Products business and the Ginzton Technology Center reported combined second quarter revenues of $7 million, down $1 million due to customer delivery schedules. "Orders were up in this business and we are continuing to step up manufacturing capacity for our security products," Guertin said.

Outlook

"For the year, we continue to believe that total company revenues should increase by about 14 percent above the fiscal 2005 total," Guertin said. "Third-quarter revenues should grow in the low double digits over the comparable period in fiscal year 2005. Excluding the impact of expensing stock options, growth in net earnings per diluted share for fiscal year 2006 should be in the range of 17 to 18 percent over the fiscal year 2005 total, and third quarter net earnings per diluted share should grow by about 14 percent over the comparable period in fiscal year 2005."

The company expects that the annual impact of stock option expensing will be in the range of $0.19 to $0.22 per diluted share in fiscal year 2006 and about $0.05 for the third quarter. The company is footnoting the impact of stock option expensing on the attached consolidated statement of earnings.

Change in Accounting

The results for the second quarter of fiscal 2006 include the impact from adoption in the first quarter of 2006 of SFAS 123® that requires expensing of stock options and other share-based payments. The company included in its cost of revenues and operating expenses total share-based compensation expenses of approximately $12 million ($7 million net of tax on earnings or $0.05 per diluted share).

For comparison purposes, the fiscal 2005 second quarter and first-half results have been adjusted to reflect a segment reporting change initiated at the beginning of fiscal year 2006. Oncology Systems results for fiscal year 2005 have been adjusted to include the company's BrachyTherapy unit and exclude the company's Security and Inspection Products business while the fiscal year 2005 results for the Other category have been adjusted to include the Security and Inspection Products business and exclude the BrachyTherapy unit.

Investor Conference Call

Varian Medical Systems is scheduled to conduct its second quarter fiscal year 2006 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at http:/es/es/es/es/es/es/es//es/es/es/es/es/es/es/www.varian.com/es/es/es/es/es/es/es/ where it will be archived for a year. To access the call via telephone, dial 1-866-383-8003 from inside the U.S. or 1-617-597-5330 from outside the U.S. and enter confirmation code 40198688. The replay can be accessed by dialing 1-888-286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 3527172. The telephone replay will be available through 5 p.m. PT, Friday, April 28, 2006. Additionally, certain non-GAAP information will be presented on the conference call. A reconciliation of such non-GAAP information to GAAP may be found on the investor relations page of the company's web site.

Varian Medical Systems, Inc. of Palo Alto, California is the world's leading manufacturer of integrated cancer therapy systems, which are used to treat thousands of patients per day. The company is also a premier supplier of X-ray tubes and flat panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,750 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. Additional information is available on the company's investor relations web site at http:/es/es/es/es/es/es/es//es/es/es/es/es/es/es/www.varian.com/es/es/es/es/es/es/es/

Note regarding reconciliation:

For comparison purposes, the company makes reference to certain net earnings and net earnings per diluted share results in the second quarter of the current fiscal year which would have been consistent with GAAP if presented in prior quarters, but which are now inconsistent with GAAP due to changes in accounting standards. These results were reached by excluding non- cash, share-based compensation expenses. The company references those results to allow a better comparison of results in the current period to those in prior periods. The company's reference to these results should be considered in addition to results that are prepared under current accounting standards but should not be considered a substitute for results that are presented as consistent with GAAP.

Forward-Looking Statements

Except for historical information, this news release contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including market acceptance of or transition to new products or technology such as intensity modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT); growth drivers; the company's orders, revenues, backlog, or earnings growth; future financial results and any statements using the terms "should," "believe," "expect," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include demand for the company's products; the company's ability to develop and commercialize new products; the company's ability to meet demand for manufacturing capacity; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase operating margins; the impact of competitive products and pricing; the effect of economic conditions and currency exchange rates; the effect of changes in accounting principles; the company's ability to meet Food and Drug Administration and other regulatory requirements for product clearances or to comply with Food and Drug Administration and other regulatory regulations or procedures; the possibility that material product liability claims could harm future revenues or require the company to pay uninsured claims; the effect of environmental claims and expenses; the company's ability to protect the company's intellectual property; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the impact of managed care initiatives or other health care reforms on capital expenditures and/es/es/es/es/es/es/es/or third-party reimbursement levels; the potential loss of key distributors or key personnel; consolidation in the X-ray tubes market; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company's business; the risk of operations interruptions due to terrorism, disease (such as Severe Acute Respiratory Syndrome and Avian Influenza) or other events beyond the company's control; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission. The company assumes no obligation to update or revise the forward- looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
        Elisha Finney  650-424-6803
        elisha.finney@varian.com

        Spencer Sias  650-424-5782
        spencer.sias@varian.com

  A summary of earnings and other financial information follows.


            Varian Medical Systems, Inc. and Subsidiary Companies
                     Consolidated Statements of Earnings
                                 (Unaudited)

  (Dollars and shares in millions,
   except per share amounts)
                           Q2 QTR      Q2 QTR         Q2 YTD       Q2 YTD
                            2006        2005           2006         2005

  Net orders              $428.8        395.0        831.1        729.3
   Oncology Systems        364.7        336.5        691.4        613.7
   X-Ray Products           58.2         53.9        113.4        103.7
   Other                     5.9          4.6         26.3         11.9

  Order backlog         $1,262.0      1,050.0      1,262.0      1,050.0

  Revenues                $413.9        350.8        748.1        649.8
   Oncology Systems        346.5        293.1        622.8        541.1
   X-Ray Products           60.7         50.2        112.9         94.6
   Other                     6.7          7.5         12.4         14.1

  Cost of revenues (1)    $242.8        200.7        438.2        374.5

  Gross margin             171.1        150.1        309.9        275.3
  As a percent of
   revenues                41.3%        42.8%        41.4%        42.4%

  Operating expenses
   Research and
    development (1)         25.0         20.2         47.2         38.6
   Selling, general and
    administrative (1)      66.6         50.6        123.4         96.8

  Operating earnings        79.5         79.3        139.3        139.9
   As a percent of
    revenues               19.2%        22.6%        18.6%        21.5%

  Interest income, net       2.6          0.6          4.2          1.1

  Earnings before taxes     82.1         79.9        143.5        141.0

  Taxes on earnings (1)     26.3         25.7         46.5         46.5

  Net earnings (1)         $55.8         54.2         97.0         94.5

    Net earnings per
     share - basic: (1)    $0.42         0.41         0.74         0.71

    Net earnings per
     share - diluted: (1)  $0.41         0.39         0.71         0.68

  Shares used in the
   calculation of net
   earnings per share:
   Average shares
    outstanding - basic    131.9        133.1        131.5        133.5
   Average shares
    outstanding - diluted  136.8        138.4        136.4        139.2


  (1)Includes the following amounts for expensing stock options and other
  share-based payments
  (in millions, except per share amounts)
                           Q2 QTR       Q2 QTR       Q2 YTD       Q2 YTD
                            2006         2005         2006         2005

  Costs of revenues         $2.0           --          3.0           --
  Research & development     1.2           --          2.1           --
  Selling, general &
   administrative            8.5           --         14.6           --
  Total                     11.7           --         19.7           --
  Taxes on earnings        (4.3)                     (6.9)

  Net earnings              $7.4           --         12.8           --

  Net earnings per
   share - basic           $0.06           --         0.10           --
  Net earnings per
   share - diluted         $0.05           --         0.09           --


            Varian Medical Systems, Inc. and Subsidiary Companies
                         Consolidated Balance Sheets

  (In thousands)                                March 31,    September 30,
                                                   2006           2005
                                               (Unaudited)
  Assets
  Current assets
   Cash and cash equivalents                      $266,265       $243,086
   Short-term marketable securities                127,290        135,356
   Accounts receivable, net                        371,301        351,899
   Inventories                                     177,365        164,873
   Other current assets                            128,801        121,681
     Total current assets                        1,071,022      1,016,895

  Property, plant and equipment                    309,711        296,862
   Accumulated depreciation and amortization     (189,900)      (182,322)
     Net property, plant and equipment             119,811        114,540

  Long-term marketable securities                        -          3,679
  Goodwill                                         121,389        121,389
  Other non-current assets                          67,752         60,899
  Total assets                                  $1,379,974     $1,317,402

  Liabilities and Stockholders' Equity
  Current liabilities
   Accounts payable                                $70,643        $71,007
   Accrued expenses                                282,826        315,287
   Product warranty                                 39,421         39,407
   Advance payments from customers                 128,277        115,543
   Current maturities of long term debt              2,697          2,689
     Total current liabilities                     523,864        543,933
  Long-term accrued expenses and other              55,837         57,124
  Long-term debt                                    57,210         57,318
     Total liabilities                             636,911        658,375

  Stockholders' Equity
  Common stock                                     131,805        130,715
  Capital in excess of par value                   239,225        150,466
  Retained earnings and accumulated other
   comprehensive loss                              372,033        377,846
     Total stockholders' equity                    743,063        659,027
  Total liabilities and stockholders' equity    $1,379,974     $1,317,402

SOURCE: Varian Medical Systems, Inc.

CONTACT: Elisha Finney, +1-650-424-6803, or elisha.finney@varian.com, or
Spencer Sias, +1-650-424-5782, or
spencer.sias@varian.com, both of Varian
Medical Systems

Web site: http:/es/es/es/es/es/es/es//es/es/es/es/es/es/es/www.varian.com/es/es/es/es/es/es/es/